Related Experiment Videos
Haloenol lactone: a new synergist of chemotherapy in vitro
J Zheng1, G T Wurz, T B Cadman
1Department of Environmental Toxicology, University of California at Davis, Davis, California 95616, USA.
Abstract:
Over-expression of glutathione S-transferases (GST) has been found to play a significant role in multiple drug resistance in cancer chemotherapy. To combat GST-mediated drug resistance, GST inhibitors are being studied as potential synergists for effective cancer chemotherapy. We have designed and synthesized a haloenol lactone derivative as a mechanism-based inactivator of GST-pi isozyme. In the current study, we examined the inhibitory effect of the haloenol lactone compound on GST of a human renal carcinoma cell line UOK130 and found that this compound shows time-dependent GST inhibition in these cancer cells. The enzyme activity lost upon incubation with the haloenol lactone could not be restored by extensive dialysis against buffer. Pretreatment of the cancer cells with 1.0 microM of haloenol lactone increased cytotoxicity induced by cisplatin in the UOK130 cell line. This report further supports the possibility of synergizing alkylating agents in cancer chemotherapy by use of selective GST inhibitors.
Insights
A novel haloenol lactone compound effectively inhibits glutathione S-transferases (GST) in human renal carcinoma cells. This inhibition enhances the efficacy of cisplatin chemotherapy, offering a potential strategy against drug-resistant cancers.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Glutathione S-transferases (GST) overexpression contributes to multiple drug resistance in cancer chemotherapy.
- GST inhibitors are investigated as sensitizers to overcome this resistance.
- A haloenol lactone derivative was designed as a mechanism-based GST-pi inactivator.
Purpose of the Study:
- To investigate the inhibitory effect of a haloenol lactone compound on GST in a human renal carcinoma cell line (UOK130).
- To assess the compound's potential to enhance the cytotoxicity of cisplatin in UOK130 cells.
Main Methods:
- Synthesis and characterization of a haloenol lactone derivative.
- Enzyme inhibition assays on GST from UOK130 cells.
- Time-dependent inhibition studies and reversibility assays (dialysis).
- Cytotoxicity assays assessing cisplatin in combination with the haloenol lactone.
Main Results:
- The haloenol lactone compound demonstrated time-dependent inhibition of GST in UOK130 cells.
- The observed GST inhibition was irreversible, as enzyme activity was not restored after dialysis.
- Pretreatment with 1.0 microM haloenol lactone significantly increased cisplatin-induced cytotoxicity in UOK130 cells.
Conclusions:
- The synthesized haloenol lactone is an effective, irreversible inhibitor of GST in renal carcinoma cells.
- This compound shows promise as a synergistic agent to enhance chemotherapy efficacy against drug-resistant cancers.
- Selective GST inhibitors may be valuable in overcoming resistance to alkylating agents in cancer treatment.